European Sero-Epidemiology Network: standardisation of the assay results for pertussis

Giammanco, Anna; Chiarini, A; Maple, P. A. C.; Andrews, Nick; Pebody, Richard; Ölander, Rose‐Marie; F, Fivet-Groyne; Baron, S.; Tischer, Annedore; Swidsinski, Sonja; Schellekens, J. F. P.; Reizenstein, Elisabet

doi:10.1016/s0264-410x(03)00514-0

Cited by 96 publications

(101 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To achieve quantitative comparability of assay results between countries, the results were standardized using a previously described methodology [26]. Briefly, the process involved the creation of a panel of 150 samples: 50 negative sera (<5 ESEN units/ml), 12 low positive (5-10 ESEN units/ml) and 88 positive (>10 ESEN units/ml) sera for PT IgG antibody by the reference laboratory (University of Palermo, Italy).…”

Section: Standardization : Panel Distribution and Testingmentioning

confidence: 99%

“…The country-specific standardization equations were used to convert local quantitative results of serum survey into standardized reference laboratory unitage. Details of the country-specific assays and standardization methodology have been described recently [26].…”

Section: Main Serum Survey Testingmentioning

confidence: 99%

“…The anti-PT antibody results from each country have been statistically standardized against a reference laboratory [26] and the results interpreted together with standardized immunogenicity data from a variety of vaccine trials, with knowledge of the countryspecific historical vaccine schedules, the types of vaccines used and the reported vaccine coverage. This provides a unique opportunity to better understand the true extent of infection across the population in each country and to compare the impact of a variety of intervention strategies.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The seroepidemiology of Bordetella pertussis infection in Western Europe

Pebody¹,

GAY²,

et al. 2004

View full text Add to dashboard Cite

SUMMARYHigh titres of pertussis toxin (PT) antibody have been shown to be predictive of recent infection with Bordetella pertussis. The seroprevalence of standardized anti-PT antibody was determined in six Western European countries between 1994 and 1998 and related to historical surveillance and vaccine programme data. Standardized anti-PT titres were calculated for a series of whole-cell and acellular pertussis vaccine trials. For the serological surveys, high-titre sera (>125 units/ml) were distributed throughout all age groups in both high-(>90 %) and low-coverage (<90 %) countries. High-titre sera were more likely in infants in countries using high-titre-producing vaccines in their primary programme (Italy, 11 . 5% ; Western Germany, 13 . 3 % ; France, 4 . 3% ; Eastern Germany, 4 . 0%) compared to other countries (The Netherlands, 0 . 5 %; Finland, 0 %). Recent infection was significantly more likely in adolescents (10-19 years old) and adults in high-coverage countries (Finland, The Netherlands, France, East Germany), whereas infection was more likely in children (3-9 years old) than adolescents in low-coverage (<90% ; Italy, West Germany, United Kingdom) countries. The impact and role of programmatic changes introduced after these surveys aimed at protecting infants from severe disease by accelerating the primary schedule or vaccinating older children and adolescents with booster doses can be evaluated with this approach.

show abstract

Section: Standardization : Panel Distribution and Testingmentioning

confidence: 99%

Section: Main Serum Survey Testingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The seroepidemiology of Bordetella pertussis infection in Western Europe

Pebody¹,

GAY²,

et al. 2004

View full text Add to dashboard Cite

show abstract

“…This methodology has been applied successfully for various vaccine-preventable infections during the ESEN projects, i.e. : (i) measles, mumps, rubella [16,20] ; (ii) pertussis [17] ; (iii) diphtheria [19]) ; (iv) VZV [18] ; and (v) HBV [21]. The present collaborative work describes the development of a standardization procedure that allows for direct comparisons of HAV seroprevalence data generated at 15 European laboratories.…”

Section: Discussionmentioning

confidence: 99%

“…However, inter-laboratory variation, even when using the same EIA and international standards, is a well-recognized problem [15][16][17][18][19][20][21]; accordingly, differences mostly in sensitivity, but also in specificity, have been reported for both commercial and in-house anti-HAV assays [22][23][24][25][26][27][28][29][30][31]. Standardization is a methodological approach that provides a means to overcome this limitation and to ensure the direct comparability of seroepidemiological results obtained during the project [32].…”

Section: Introductionmentioning

confidence: 99%

The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries

Anastassopoulou

Kafatos²,

Nardone³

et al. 2008

Epidemiol. Infect.

View full text Add to dashboard Cite

SUMMARYThe European Sero-Epidemiology Network 2 (ESEN2) aimed to compare serological results of vaccine-preventable diseases across Europe. To ensure direct inter-country comparability of hepatitis A virus antibody (anti-HAV) measurements, a standardization panel of 150 sera was developed by a designated reference laboratory and tested by participating national laboratories using assays of choice ; each country's results were subsequently regressed against those of the reference laboratory. Quantitatively, the assays were generally highly correlated (R 2 >0 . 90). Nevertheless, qualitative comparisons indicated that results obtained with different assays may differ despite the usage of well-established international and local standards. To a great extent standardization successfully alleviated such differences. The generated standardization equations will be used to convert national serological results into common units to enable direct international comparisons of HAV seroprevalence data. The results of this study are expected to contribute to the evaluation and potential improvement of the currently employed immunization strategies for hepatitis in Europe.

show abstract